The Food and Drug Administration approved the first mRNA flu vaccine in United States history on Wednesday, clearing Moderna’s mFlusiva for adults 50 and older. The decision hands the company its fourth approved product and opens a new chapter for a virus that fills emergency rooms every winter. Getting here took a fight inside the agency itself.
Millions of older Americans could see the shot on pharmacy shelves within weeks. The approval also tests whether messenger RNA technology, built during the Covid-19 pandemic, can outperform vaccines Americans have used for decades.
A rejection turned into a reversal before approval came through
The road to Wednesday’s decision was not straight. In February, Vinay Prasad, the FDA’s vaccines chief at the time, overruled his own career reviewers and issued a rare refusal-to-file notice. This blocked the agency from even reviewing Moderna’s data package.
A week later, after Moderna went public with the rejection and its own objections, Prasad’s decision was reversed. The about-face opened the door to a formal review that stretched across six months before ending in approval this week.
Moderna’s fourth cleared US product joins two Covid-19 vaccines and an RSV shot, mRESVIA, already sold to older adults. That RSV vaccine won approval on a 37,000-person trial and posted 83.7% efficacy against severe lower respiratory disease, edging out rival shots from Pfizer and GSK. The flu shot extends that same platform into a bigger market.
The new shot beat a standard flu vaccine by a wide margin
Moderna tested mFlusiva in a late-stage trial enrolling more than 40,000 adults 50 and older during the 2024-2025 respiratory virus season, comparing it directly against a licensed comparator shot rather than a placebo. The company reported the mRNA vaccine was about 27% more effective at preventing flu illness than the standard shot given to the same age group. Moderna chief executive Stephane Bancel called the clearance proof of the ongoing potential of our mRNA platform, framing it as validation for a technology first proven at scale during the pandemic.
Reported side effects mirrored what Moderna’s Covid shots have produced. Patients experienced injection-site pain and swollen lymph nodes alongside fatigue, headache and muscle soreness. Nothing in the data raised a new safety flag serious enough to hold up review once the FDA agreed to look at it.
Manufacturing speed may matter more than the efficacy number
Flu strains get locked in months before the virus even starts circulating, a gamble that sometimes misses. Moderna says it can move from selecting a strain to shipping finished vaccine in two to three months, versus roughly six months for traditional shots. That shorter runway lets manufacturers wait longer before finalizing a formula, narrowing the window for a late mutation to spoil the match.
Traditional flu vaccines have swung anywhere from 22% to 56% effective depending on how well predictions held up each year. Many scientists and public health experts have touted the idea of an mRNA-based flu vaccine.
The approval comes with strings attached for the oldest patients
The FDA split its clearance in two. Adults 50 to 64 received full approval, while adults 65 and older got the shot under accelerated approval, a pathway that depends on Moderna confirming clinical benefit in a required postmarketing trial rather than waiting years for that proof upfront. For patients 65 and older, the accelerated clearance rested on immune response data instead of the direct effectiveness findings used for the younger group.
The dispute that delayed review centered on that same trial, which Prasad’s refusal letter faulted for not including a vaccine brand recommended for people 65 and older. Moderna revised its application to seek two separate approval tracks rather than one and agreed to run the additional study as a condition of clearance.
Seniors carry the heaviest cost of a mismatched flu season
The stakes explain why regulators focused so heavily on older adults.
During the 2024-2025 season, the CDC estimates flu caused:
- 51 million illnesses
- 710,000 hospitalizations and 45,000 deaths nationwide
Adults 65 and older accounted for:
- 57% of those hospitalizations
- 71% of the deaths
Adults 50 to 64, the group that received full approval Wednesday, made up another 20% of hospitalizations and 21% of deaths that same season.
Separately, the agency estimates that across most recent seasons, people 65 and older have made up between 70% and 85% of all flu deaths despite representing a much smaller share of the population. Weakened immune defenses that come with age largely explain the gap, and it is the reason regulators pushed so hard on data from exactly this group before signing off.
Vaccine politics shadowed the science throughout
Approval landed despite public skepticism of mRNA technology from Health and Human Services Secretary Robert F. Kennedy Jr., whose department oversees the FDA. Moderna announced the clearance Wednesday evening after months of tension between the company and agency leadership over the underlying trial data. That tension played out unusually publicly for a regulatory review, with Moderna disclosing both the initial refusal and its own frustration before the agency reversed itself.
The friction never fully disappeared even after the FDA agreed to review the application. The gap between that reversal and Wednesday’s sign-off ran several months, and neither the agency nor Moderna has detailed what filled it.
The vaccine could reach retailers within weeks and other countries by next year
Moderna expects mFlusiva available for eligible patients during the 2026-2027 respiratory virus season, joining Spikevax, mRESVIA and mNEXSPIKE in the company’s US lineup. The vaccine, known scientifically as mRNA-1010, has already been accepted for regulatory review in the European Union, Canada and Australia, with more international filings planned later this year.
That timeline puts a domestic rollout on pace with the traditional fall vaccination push. Traditional flu shots still rely on egg-based manufacturing that takes roughly six months from strain selection to rollout, the gap mFlusiva is built to close. Whether pharmacies stock it alongside standard shots or price it as a premium option will shape how fast the technology catches on.
